What is the importance of difference in LCM strategy in drug development? – Learnings from Keytruda and Opdivo

Kodama, Kota; Djurian, Arisa; Lim, Yeongjoo

doi:10.1016/j.drudis.2022.103390

Drug Discovery Today

2022

DOI: 10.1016/j.drudis.2022.103390

|View full text |Cite

What is the importance of difference in LCM strategy in drug development? – Learnings from Keytruda and Opdivo

Kota Kodama

Arisa Djurian

Yeongjoo Lim

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Challenges and advances of immune checkpoint therapy

Li,

Sun

2024

Clinical and Translational Dis

View full text Add to dashboard Cite

Background and ObjectivesImmuno‐checkpoint therapy (ICT) significantly alters the clinical course of cancer patients, providing long‐lasting clinical benefits and offering the potential for cure to some patients. However, response rates for different tumour types vary, and predictive biomarkers are needed to enhance patient selection for the purpose of optimising effectiveness and reducing toxicity. This has driven efforts to decipher the immune and non‐immune factors that regulate ICT response.Main ContentThis review offers a thorough examination of the advantages and future challenges of immune checkpoint inhibitors in cancer therapy. Additionally, we explore ongoing efforts to address current challenges, such as guiding subsequent clinical trials, developing ICT combination therapy strategies and utilising epigenetics to enhance clinical efficacy.Conclusion and PerspectivesDespite significant progress, ICT faces challenges including immune‐related adverse events (irAEs) and resistance mechanisms. Ongoing research focuses on developing novel biomarkers, combination therapies, and epigenetic strategies to improve the efficacy and safety of ICT for cancer patients worldwide. Future studies are required to validate these findings across different tumor types and treatment settings.

show abstract

Challenges and advances of immune checkpoint therapy

Li,

Sun

2024

Clinical and Translational Dis

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

What is the importance of difference in LCM strategy in drug development? – Learnings from Keytruda and Opdivo

Cited by 1 publication

References 16 publications

Challenges and advances of immune checkpoint therapy

Challenges and advances of immune checkpoint therapy

Contact Info

Product

Resources

About